B&K CORPORATION LIMITED (“the Company”,Stock Code: 02396.HK) is an innovative China-based biopharmaceutical company with a global vision. Since its establishment in 2012, the company has been consistently dedicated to addressing unmet clinical needs and developing innovative protein therapeutics. We firmly believe that genuine innovation stems from profound disease insights and clear clinical positioning. We are deeply focused on the large and continuously expanding specialized field of wound healing and tissue repair, and are fully advancing the R&D and commercialization of our core products - platelet-derived growth factor (PDGF) drugs. Our mission is to tackle the practical challenges faced by patients with chronic and acute wounds, and bring benefits to more patients worldwide.

As at 31 December 2025, we have built a diversified pipeline consisting of ten drug candidates. Of these, our two core products are as follows:  1) Pro-101–1, which is being prepared for the Phase IIIa clinical trial in China, and we expect to complete the Phase IIIa clinical trials in 2027Q1; and 2) Pro-101–2, which is undergoing the Phase II clinical trial in China, and we expect to complete the Phase II clinical trials in 2027Q2.